The term “autism” comes from the Greek and means “to be very self-reliant”. By Leo Kanner and Hans Asperger the term was first used for children with a profound developmental disorder. Autistic disorders can be very different. Today we speak of autism spectrum disorders (ASD).
People with a disorder from the autism spectrum perceive their environment differently (autistic perception). They can barely empathize with other people and communicate adequately with them. They cannot recognize the mood of their counterpart from his face. Contacts are rather avoided. They are happy to deal with a specialty. They have difficulty adjusting to the new and the desire to make everyday routines always the same (rituals). Often they are oriented towards details and have difficulty comprehending a situation holistically. In many cases, those affected are rather awkward in their movements.
Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. It refers to a range of conditions characterized by anxiety, repetitive patterns of behavior, impairments in social communication including verbal and non-verbal communication, and deficits in developing and maintaining relationships. Although autism can be diagnosed at any age, it is said to be a “developmental disorder” because symptoms generally appear in the first two years of life. While scientists currently don’t know the exact causes of ASD, research suggests that genes can act together with influences from the environment to affect development in ways that lead to ASD.
The category includes conditions that were formerly considered separate: Autism, Asperger’s syndrome, childhood disintegrative disorder (CDD), and pervasive developmental disorders (unspecified) (PDD).
One in 59 children are diagnosed with ASD, implying that ASD affects approximately one million children and adolescents in USA between the ages of 5 and 17.
Accelerating rate of diagnosis, but only two FDA approved drugs
- Both are atypical antipsychotics, which have significant side effect profiles
- Neither approved to address the key symptoms of social impairment and anxiety
Newer studies suggest ASD is linked to disruption in the Endocannabinoid system (EC-System)
- Altered anandamide signaling may contribute to ASD-related social and communication impairments
- EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergic, glutamatergic transmission, oxidative stress, immune dysregulation and altered energy metabolism
- Clinical and anecdotal data show improvement in social avoidance and anxiety in children with CBD
- CBD may modulate the EC-System and improve certain autism-related behaviors
Our Biotech company is developing the first and only pharmaceutically-manufactured CBD gel formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin).
In the second quarter of 2019, our Biotech pearl initiated a clinical study on the use of the CBD gel in the use and treatment of neuropsychiatric symptoms at ASD. The first results are already expected in the first half of 2020!
We added this fundamentally strong biotech company (with a focus on cannabinoids!) on August 30, to our watchlist and introduced the company to our exclusive cannabis radar community. In our opinion, the company is the new “GW Pharma 2.0” because there are many similarities to GW Pharma. However, the market capitalization is only $ 250 million instead of $ 4.3 billion!
Subscribe to our free newsletter now – with detailed information, market commentary, active traded model portfolio and trade signals to promising cannabis company.
After registering for our free newsletter, you will receive your password for the premium content area at: https://cannabisradar.de/premium-content/ and you can download all previous trade signals and former newsletter issues!
We can very well imagine that our new cannabinoid biotech gem will be able to evolve in a similar way to our sample pot value GW Pharmaceuticals!
GW Pharma has skyrocketed from $ 10 to $ 200 in just 6 years. GW Pharmaceuticals launched an FDA-approved drug (Epidiolex with CBD) in 2018 for the treatment of rare epileptic diseases.
We expect a similar success story of our biotech pick when the patented CBD gel is being approved by the FDA or another drug regulation authority for the treatment of various neuropsychiatric disorders!